Loading...

SCYX SCYNEXIS INC Investments/Divestments 8-K Filing

SCYN

SCYX

SCYNEXIS INC

(SCYX)

2024 8-K

Stock Split Announcement

Stock Split Approval

Director's Retirement

Conference Call Update

Private Placement Announcement

Asset Acquisition

License Agreement Update

Voluntary Delisting

Stock Offering Agreement

Investor Update

Annual Meeting of Stockholders

Quantitative Data

Regulation FD Disclosure

Amendment to License Agreem...

Recall and Clinical Hold

Recall and Clinical Study Hold

Termination of Loan Agreeme...

Annual Meeting of Stockholders

Quantitative Data

External Links:

SCYNEXIS Inc. and GlaxoSmithKline have entered into a binding memorandum of understanding to amend their exclusive license agreement for the development and commercialization of ibrexafungerp, with SCYNEXIS eligible to receive milestone payments and royalties from GSK.

AI Assistant

SCYNEXIS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.